Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
ความหวังใหม่สำหรับผู้ป่วยโรคมีเลือดมาก (Multiple Myeloma) – เริ่มต้นการรักษาด้วย CAR-T Therapy
🎯ความหวังใหม่สำหรับผู้ป่วยโรคมีเลือดมาก (Multiple Myeloma) – เริ่มต้นการรักษาด้วย CAR-T Therapy🎯
⭐เมื่อเร็ว ๆ นี้ ทีมของศาสตราจารย์ ดร. ลิ ปิง ณ โรงพยาบาลตงจิ ในเซี่ยงไฮ้ ได้ดำเนินการรักษาด้วยการภูมิคุ้มกันเซลล์ T ที่มีภูมิลักษณ์ผสม (Chimeric Antigen Receptor T-Cell Immunotherapy หรือ CAR-T) สำเร็จสำหรับผู้ป่วยโรคมีเลือดมากที่ซ้ำกลับและซ้ำแล้วและซ้ำไม่ได้ (R/RMM) นี่เป็นการรักษาที่เปิดโอกาสใหม่สำหรับการรักษาผู้ป่วย R/RMM
🌟ผู้ป่วยที่ได้รับการรักษาด้วย CAR-T นี้ได้รับการวินิจฉัยว่าเป็นโรคมีเลือดมากในเดือนกรกฎาคม พ.ศ. 2564 ในประเทศไทย โรคมีเลือดมากของผู้ป่วยมีภาระรักษามาก โรครุนแรง แม้จะได้รับการรักษาด้วยเคมีบำบัดระบบทั่วไป โมโนคลอนอนิบอดี้ การปลูกถ่ายเซลล์ลำไส้โภชนาการของตนเอง (ASCT) และการรักษาอื่น ๆ โรคยังกลับมาซ้ำกลับหลายครั้ง ในระยะเวลาของโรคเพียง 2 ปี เข้าสู่การรักษาหลายเส้นทาง และเจริญสามารถรับการรักษาอย่างเป็นตัวอย่าง ไม่สามารถควบคุมโรคได้อย่างมีประสิทธิภาพ
🌠 เมื่อจำนวนการเกิดการซ้ำกลับเพิ่มขึ้นในผู้ป่วย R/RMM และจำนวนของเส้นทางการรักษาขยายออก การตอบสนองต่อการรักษาก็เลวร้ายลงและระยะเวลาของการหายตัวยังกลับมาสั้นลง อย่างไรก็ตาม ด้วยการอนุมัติยา CAR-T therapy ที่เป็นมนุษย์ที่สมบูรณ์แบบแรกในโลก ชื่อ FUCASO (Eque-cel) ในจีนใหญ่ ความหวังใหม่ก็ได้ถูกเปิดขึ้นอย่างไม่สงบสำหรับการรักษาโรคมีเลือดมาก โครงสร้าง CAR ที่เป็นมนุษย์ที่สมบูรณ์แบบของมันไม่เพียงแต่มีความต้านทานต่อร่างกายน้อย แต่ยังมีการปลดตัวออกและการใช้งานต่ำ ทำให้ผู้ป่วยสามารถกลับไปสู่ระดับคุณภาพชีวิตที่สูงขึ้นด้วยการรักษาแค่ครั้งเดียว
☄หลังจากทีมของศาสตราจารย์ ดร. ลิ ปิง ประเมินพิจารณาพบว่าผู้ป่วยมีเงื่อนไขที่เหมาะสมสำหรับการรักษาด้วยเซลล์ CAR-T หลังจากการสื่อสารอย่างเต็มที่ระหว่างแพทย์กับผู้ป่วยและครอบครัวของเขา ผู้ป่วยในที่สุดก็เลือกที่จะรับการรักษาด้วย CAR-T และได้ทำการรวบรวมเซลล์โมโนเนวกลุ่มเลือดเป็นรายในเดือนพฤศจิกายน พ.ศ. 2566
✨ เราจะติดตามความคืบหน้าของการรักษาของผู้ป่วยต่อไปและรายงานติดตามต่อไป
#CARTTreatment #CARTTherapy #HopeReborn #FUCASOApproval #EquecelApproval #MultipleMyeloma #TongjiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART
หมายเหตุ: ภาพถ่ายและข้อมูลได้รับอนุญาตจากโรงพยาบาล ผู้ป่วย และครอบครัวของผู้ป่วย
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
2024 Lancet: Revolutionizing Cancer Treatment: China’s Breakthroughs in CAR T-Cell Therapy
🌟2024 Lancet: Revolutionizing Cancer Treatment: China’s Breakthroughs in CAR T-Cell Therapy 🌏
LANCET
Dive into the cutting-edge world of CAR T-cell therapy, where China is making waves in the realm of cellular treatments. Since the inception of CAR T-cell clinical trials in 2013, this groundbreaking therapy has become a beacon of hope for cancer patients across the country.
🔬 Explosive Growth: By 2017, China led the globe in the number of CAR T-cell-related clinical trials, marking a pivotal moment in the evolution of cancer treatments. Fast forward to 2021, and Chinese cell therapy companies have amassed a staggering $237 million in funding, reflecting the robust expansion of CAR T-cell therapy in the nation.
🌐 Government Support: A deep dive into the research unveils the influential role of Chinese government policies in propelling CAR T-cell therapy forward. Strong governmental backing, coupled with capital influx, massive patient demand, and a unique healthcare system, lays the foundation for the accelerated growth of this revolutionary therapy in China.
🎗️ Overcoming Challenges: While CAR T-cell therapy is still in its infancy for solid tumors, it has achieved remarkable success in treating blood cancers. China has emerged as a global leader in conducting clinical trials, particularly focusing on hematologic malignancies like B-cell lymphomas. CAR-T cells, reprogrammed to combat cancer, offer a beacon of hope for those facing these formidable diseases.
🚀 Pushing Boundaries: Beyond blood cancers, Chinese researchers are actively exploring the potential of CAR-T cell therapy in various solid tumors. Preliminary studies hint at promising results for liver, pancreatic, and brain cancers. China’s commitment to medical innovation shines through as it pushes the boundaries of cancer research and treatment strategies.
🌈 Hope for the Future: Join us in celebrating the strides China is making in cancer research. Every breakthrough in CAR T-cell therapy brings us closer to a future where cancer is not just treated but conquered.
💪🏼🔬 #CARTCellChina #MedicalInnovation #CancerBreakthrough #HopeForTheFuture #GlobalHealthRevolution #CellTherapy #LANCET #HEMATOLOGY
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
The Chinese CAR-T therapy achieves a miraculous cure for advanced liver cancer, creating wonders in the field of cellular treatment for solid tumors.
The Chinese CAR-T therapy achieves a miraculous cure for advanced liver cancer, creating wonders in the field of cellular treatment for solid tumors.🌞🌞
🥰Surviving Against the Odds: A Chinese Doctor’s Journey with Liver Tumor🥰
Zou began his career in 1989 and has dedicated 30 years as an obstetrician-gynecologist, tirelessly working on the frontline of clinical care.
⭐️”One afternoon, I felt excruciating pain in my right shoulder while sitting in the office. It turned out I had three massive tumors on my liver. At that moment, I had no idea that my life had entered a countdown,” recalls Dr. Zou.⭐️
⭐️”Dr. Zou is in the advanced stage of liver cancer, with metastasis to the lungs,” urgently declared Prof.Shi as he convened a team of experts to consult on Dr. Zou’s condition.⭐️
⭐️ “With conventional treatment, the survival period is typically 3-6 months. Even with surgery, there’s no hope,” stated Prof.Shi.⭐️ Dr. Zou, a doctor himself, continued to ponder work matters, but colleagues and loved ones were tirelessly searching for any possible cure.
⭐️”Prof.Shi mentioned this immunotherapy, an antibody treatment,” said Dr. Zou’s wife.⭐️
Antibody therapy, specifically Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T), is a novel precision-targeted treatment for tumors. Using genetic engineering, T-cells are activated and equipped with a guided navigation device called CAR (Chimeric Antigen Receptor), transforming ordinary warriors into super soldiers known as CAR-T cells. These cells specifically recognize and efficiently eliminate tumor cells, achieving the goal of treating malignant tumors.
Fortunately, Dr. Zou’s health indicators perfectly matched the criteria for CAR-T therapy, providing him with a chance to defy death.
⭐️”In the early stages, I needed treatment every two weeks. Finally, after five or six sessions, my cancer cells started degenerating and liquefying. By now, the last and originally largest tumor has significantly liquefied and been absorbed,” Dr. Zou said.⭐️
⭐️”A miracle happened. We have taken a significant step in overcoming liver cancer in humans,” Prof.Shi added.⭐️
As the treatment gradually took effect, Dr. Zou’s health improved, allowing him to resume his daily work. After completing the treatment cycle, Dr. Zou once again donned the white coat, transitioning from patient to doctor.
In his heart, a stronger belief in the sincerity towards the medical profession and the health of patients emerged.
#SurvivorStories #MedicalMiracle #Inspiration #CancerSurvivor #CARTTherapy #AgainstAllOdds #HealthJourney #BelieveInMiracles #advancedmedicineinchina #chinesemedicine
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
A Miraculous Journey: Israeli Artist Finds Cure for Multiple Myeloma in Hangzhou China
A Miraculous Journey: Israeli Artist Finds Cure for Multiple Myeloma in Hangzhou China
In a remarkable medical story, we turn our attention to the experiences of a friend seeking treatment in Hangzhou China. Tali, a well-known artist from Israel. In 2012, she was diagnosed with multiple myeloma, a malignant blood disease, and after seeking treatment in various European countries, including Israel and France, she found no definitive cure. In a moment of despair, she discovered a solution from Hangzhou, China, through the European Bone Marrow Transplant Association.
On October 6th, Tali and her family boarded a flight from Israel to Hangzhou. Under the meticulous care of Professor Huang He and his team at Zhejiang University’s First Hospital, Tali underwent over a month of intensive treatment. Today, Tali is finally on the road to recovery, expressing her gratitude to the medical staff through her preferred medium – art.
In the hospital room, Tali and Professor Huang He share laughs and conversations. The weather looks promising, initially being skeptical about her health when arriving in Hangzhou, encouragement from the medical team reignited her hope for recovery. Using her artistic language, she documented every moment of the treatment process.
After undergoing treatment, the excruciating bone pain gradually lessened, indicating a positive turn in her health.
“I can feel my body improving bit by bit. Green cells are gradually replacing the red ones, and my bone pain has completely disappeared. There are no tumor cells in the bone marrow anymore – they have vanished entirely.” Tali expressed.
The advanced treatment utilized at Zhejiang University’s First Hospital involves cutting-edge blood cell separation technology. Lymphocytes are extracted and genetically engineered to attack malignant tumor cells, successfully curing multiple myeloma. This revolutionary technique is known as CAR-T cell therapy. Zhejiang University’s First Hospital stands out as one of the earliest and most experienced clinical research centers using this technology, making it a pioneer in the field.
In here we bring you this inspiring story from Hangzhou, where art, science, and the human spirit come together in a tale of triumph over adversity.
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Breakthrough Ultra CAR-T Therapy Shows High Disease Control Rate of 85.7% in Advanced Platinum-Resistant Ovarian Cancer
Breakthrough Ultra CAR-T Therapy Shows High Disease Control Rate of 85.7% in Advanced Platinum-Resistant Ovarian Cancer
As a skilled overseas social media writer, here’s a revamped article for international media promotion:
In a groundbreaking development, PRGN-3005, an Ultra CAR-T cell therapy, is making waves with an impressive disease control rate (DCR) of 85.7% in the treatment of advanced platinum-resistant ovarian cancer. Utilizing non-viral gene delivery technology, this therapy eliminates the need for ex vivo expansion, significantly reducing production time and costs. The ability to administer the treatment rapidly, as soon as the second day after non-viral gene transfer, not only lowers production time and costs but also enhances tumor targeting precision. This holds the potential to disrupt the current landscape of CAR-T cell therapy.
Published in the Journal of Clinical Oncology, the “Phase 1/1b Clinical Trial of PRGN-3005 in Recurrent or Refractory (r/r) Ovarian Cancer” reported promising outcomes. The study included 25 assessable patients with a median age of 64 (range: 38-76) who had undergone extensive pretreatment with a median of 8 prior therapeutic regimens. The patients were divided into three groups: intraperitoneal (IP) infusion (C1, n = 12), intravenous (IV) infusion (C2, n = 6), and intravenous cyclophosphamide low dose (IV LD, n = 7).
Post-treatment, 20% of all participants exhibited regression in at least one target lesion (evaluated by RECIST 1.1 criteria). Notably, the DCR for the IV LD group was an impressive 85.7%, with a 57% reduction in target tumor burden and an average 27.4% decrease in CA125. A patient in the IV LD group experienced a 28% reduction in target tumor burden after a second PRGN-3005 infusion at the 12-month mark. Importantly, no PRGN-3005-related dose-limiting toxicities, neurotoxicities, or ≥3-grade cytokine release syndrome (CRS) adverse reactions were observed.
These results underscore the favorable tolerability of PRGN-3005 Ultra CAR-T therapy in treating ovarian cancer, demonstrating an encouraging disease control rate (DCR) and an overall reduction in tumor burden.
While CAR-T therapy has shown great promise in treating hematologic malignancies and several products have been approved, its application in solid tumor treatment is still in the clinical experimental stage. Nevertheless, with the continuous evolution of CAR-T generations, the emergence of more prominent targets, and improvements in proliferation and cytokine release aspects, the conquest of advanced solid tumors by CAR-T therapy seems imminent. Numerous clinical trials are already underway, offering hope for complete remission in fortunate patients.
#PRGN3005 #CARTTherapy #OvarianCancer #MedicalBreakthrough #CancerTreatment #Ovarian
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Breakthrough CAR-T Cell Therapy for R/R B-Cell ALL: A Game-Changer in Chinese Medical Innovation
Breakthrough CAR-T Cell Therapy for R/R B-Cell ALL: A Game-Changer in Chinese Medical Innovation
ALL- Acute Lymphoblastic Leukemia
The Fourth China Hematology Development Conference – CAR-T Frontier Forum and the First CAR-T Cell Immunotherapy Summit (JCIS), held on January 5, 2024, in Tianjin.
Potential Best-in-Class: Inaticabtagene Autoleucel Redefining Long-term Outcomes for R/R B-ALL
Professor Ma Jun from the Harbin Institute of Hematology and Oncology shared notable progress in immunotherapy and cell treatment for Chinese ALL. Previously, the overall complete response (CR) rate for adult R/R ALL treatment in China was approximately 40%, with a mere 11% 3-year survival rate. The introduction of CAR-T cell therapy has been a paradigm shift, altering the long-term outcomes for R/R B-ALL patients.
Inaticabtagene Autoleucel demonstrates superior efficacy:
Higher overall response rates (ORR) at 3 months and beyond, with median duration of response (DOR) and overall survival (OS) surpassing other products.
Patients treated with Inaticabtagene Autoleucel exhibit similar long-term benefits in OS, whether or not they undergo subsequent transplantation.
Inaticabtagene Autoleucel boasts enhanced safety:
Lower incidence rates of grade 3 cytokine release syndrome (CRS), grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS), and infusion-related mortality compared to other CAR-T products.
Moreover, in minimal residual disease-positive (MRD+) B-ALL patients, CAR-T cell therapy has shown significant progress. It eradicates MRD, improves survival rates, and may serve as a first-line consolidation therapy for CR patients, aiding in:
Higher remission rates
Reduced transplant requirements, mitigating transplant-related complications
Maintenance of long-term remission for those unsuitable for allo-HSCT or unwilling to undergo it
Improved overall survival
Lower intensity and duration of intensive chemotherapy, leading to shorter treatment times and enhanced compliance.
The Future Outlook: Believing in the potential of CAR-T cell therapy, it is anticipated that this innovative treatment will extend hope to currently incurable diseases such as solid tumors and brain tumors. The strides made in Chinese medical innovation, exemplified by Inaticabtagene Autoleucel, signal a promising future for the global landscape of CAR-T cell therapy.
#CARTRevolution #InaticabtageneAutoleucel #HematologicCancerTherapy #ClinicalBreakthrough #ChinaHematologyConference #JCIS #BAllTreatment #MedicalAdvancements #CancerResearch #TreatmentInnovation #InaticabtageneAutoleucel #Autoleucel #ChineseCART #CARTTherapy #cancer #Bloodcancer #MedicineinCHINA #Medicaltourismo #Advancedmedicine #cancertherapy #leukemia
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Clinical Breakthrough: Chinese CAR-T – Inaticabtagene Autoleucel Revolutionizing Hematologic Cancer Therapy
“Clinical Breakthrough: Chinese CAR-T – Inaticabtagene Autoleucel Revolutionizing Hematologic Cancer Therapy”
On January 5, 2024, the Fourth Chinese Hematology Development Conference was convened in Tianjin, China, concurrently hosting the CAR-T Frontier Forum and the First CAR-T Cell Immunotherapy Summit (JCIS). The focus was directed towards the latest advancements and clinical applications of Inaticabtagene Autoleucel, presenting new pathways for standardized treatments.
Under the moderation of Professors Wu Depei and Hu Yu, Professor Wang Ying from the Institute of Hematology at the Chinese Academy of Medical Sciences presented a specialized lecture titled “Interpreting Key Clinical Data of Inaticabtagene Autoleucel.” Professor Wang highlighted the challenges faced by adult B-ALL patients in China, commonly treated with salvage chemotherapy ± hematopoietic stem cell transplantation. However, the median survival period is only 2-6 months, and targeted therapies yield a median survival of merely 7.7 months, necessitating an urgent need for more effective treatment methods. Recently, the Inaticabtagene Autoleucel infusion has been approved for treating adult R/R B-ALL patients.
Critical clinical research (NCT04684147) has revealed the substantial outcomes achieved with a single treatment of Inaticabtagene Autoleucel:
Rapid and profound remission: Within 3 months of treatment, the overall response rate (ORR) reached an impressive 82.1%, with a 100% negativity rate for minimal residual disease (MRD), showcasing the remarkable effects of Inaticabtagene Autoleucel within a short span.
Enduring remission: The 3-month post-treatment overall remission rate stood at 64.1%, with a 12-month sustained remission rate (DOR) of 80%. With a median follow-up of 8.0 months, the median relapse-free survival (RFS) period has not been reached. The one-year survival rates for overall infused patients, those achieving complete response (CR)/complete response with incomplete hematological recovery (CRi) within 3 months, and those reaching CR/CRi at 3 months were 67.9%, 72.0%, and 85.6%, respectively.
Good safety profile: The incidence rate of ≥3-grade cytokine release syndrome (CRS) was only 10.3%, and that of ≥3-grade immune effector cell-associated neurotoxicity syndrome (ICANS) was merely 7.7%. Moreover, patients recovered post-treatment without complications.
Furthermore, data from over 100 patients validated the clinical efficacy and safety of Inaticabtagene Autoleucel, affirming its robustness and offering renewed hope to a larger patient population. This breakthrough treatment provides a new avenue for tackling challenging diseases and is poised to revolutionize the landscape of hematologic cancer therapy.
#CARTRevolution #InaticabtageneAutoleucel #HematologicCancerTherapy #ClinicalBreakthrough #ChinaHematologyConference #JCIS #BAllTreatment #MedicalAdvancements #CancerResearch #TreatmentInnovation #InaticabtageneAutoleucel #Autoleucel #ChineseCART #CARTTherapy #cancer #Bloodcancer #MedicineinCHINA #Medicaltourismo #Advancedmedicine #cancertherapy
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Exploring Tumor Vitality: Chinese CAR-T Therapy Grants Patients Complete Remission
Exploring Tumor Vitality: Chinese CAR-T Therapy Grants Patients Complete Remission
“Is it true? It’s so unbelievable!” said Chen, the “fortunate one.”
On June 22, 2021, the approval of China’s first CAR-T cell therapy product, Yescarta, marked a significant milestone in medicine. Behind this milestone lies the story of a patient named Chen, diagnosed with diffuse large B-cell lymphoma, which not only brought confidence to patients but also injected fresh belief into medical professionals.
Chen was diagnosed with diffuse large B-cell lymphoma in July 2019, underwent primary treatment, only to unfortunately relapse. Due to the insufficient efficacy of secondary treatment and considering the TP53 mutation, conventional treatment plans were inadequate. However, the approval of Yescarta on June 22, 2021, brought a glimmer of hope for patients. Under the meticulous planning of the expert team in the Hematology Department of Ruijin Hospital, Chen successfully underwent CAR-T cell infusion therapy on August 2.
One year after the evaluation of the treatment’s effectiveness, Chen’s condition still maintains complete remission. This achievement has brought immense hope and joy to patients with diffuse large B-cell lymphoma, strengthening the belief in the potential of CAR-T therapy among medical practitioners.
“This is not only good news for patients but also an encouragement and boost to us, clinical doctors in the field of hematology,” stated Professor Xu Pengpeng.
This case represents not only a medical breakthrough but also serves as an inspiration for individuals battling diffuse large B-cell lymphoma. The success of CAR-T therapy reveals new possibilities, offering a new pathway to break the limitations of the “mere six-month survival period” in cancer treatment. May more patients benefit from this breakthrough, offering hope for healing and long-term remission.
#CARTtherapy #TumorVitality #CancerTreatment #NewMedicalTechnologies #MedicalAdvancement #Bloodcancer #cancersuvivor #lymphoma
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Two Years of Complete Remission(Lymphoma), CAR-T therapy has given her a new lease on life.
“Two Years of Complete Remission, CAR-T therapy has given her a new lease on life. She Thought the Journey Was Over”
Yun is a 78-year-old patient who achieved a continuous complete remission for two and a half years despite relapsed/refractory diffuse large B-cell lymphoma. Diagnosed in 2019, after enduring six rounds of chemotherapy, she initially achieved complete remission as confirmed by her healthcare team. Unfortunately, the period of remission was short-lived as Yun soon experienced disease relapse, and subsequent second-line treatments failed to yield positive results.
“I vividly remember when Director Wang Li encouraged me, mentioning an advanced method called Car-T, but it was quite expensive. I was hesitant, but I discussed it with my son when I got home. When my son and daughter-in-law heard about it, they insisted on treatment. My son said, ‘Mom, you’re the only mother I have in this world. As long as you’re here, our home is complete. Money can be earned again, and if the treatment isn’t successful, at least we won’t have regrets.’ I was deeply moved. At my age, I’ve already shown strength through previous treatments. I believe that wherever my health takes me is where I belong. Everyone’s support gave me a reason to stay strong again.”
In 2021, CAR-T cell therapy was approved and launched in China, and Yun underwent this treatment at Ruijin Hospital.
Dr. Wang Li, Director of Hematology at Ruijin Hospital, explained, “CAR-T cell therapy provides new treatment options for a wide range of cancer patients.”
“Before planning Yun’s CAR-T cell therapy, lymphoma experts, considering her current tumor status and medical history, anticipated potential adverse reactions during the treatment process and discussed handling protocols. Yun’s entire journey with CAR-T cell therapy was challenging. The medical team meticulously coordinated their efforts, successfully addressing adverse reactions after CAR-T treatment, ultimately averting potential risks.”
Despite lying in her hospital bed, Yun deeply appreciates the relentless dedication of her medical caregivers. “Sometimes, directors come to see me after 10 p.m., telling me they worked late but had to check on me; some arrive by my bedside as early as 7 a.m., concerned about my well-being. I continuously remind myself that I must strive, persist, and live up to the efforts made by doctors and my entire family,” said the 78-year-old Yun . “I made it through.”
#CARTCellSuccess #CancerWarrior #CompleteRemissionChronicles #FamilySupportMatters #CAR-TBreakthrough #InspiringHealthJourney #MedicalMiracles #NeverTooLateToFight #Cancerfight #Bloodcancer
#lymphoma
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Breakthrough Advances in CAR-T Cell Therapy Combined with TKI for Malignant Hematologic System Tumors
Breakthrough Advances in CAR-T Cell Therapy Combined with TKI for Malignant Hematologic System Tumors
At this year’s ASH conference, Professor Huang He, the director of the First Affiliated Hospital of Zhejiang University School of Medicine, presented a significant study on CAR-T cell therapy for B-ALL, marking a groundbreaking stride in the treatment of malignant hematologic system tumors.
This study, targeting newly diagnosed adult Ph-positive acute lymphoblastic leukemia, investigated the combined treatment of dasatinib and CAR-T cell therapy as a frontline therapy for initial patients. The integration of CAR-T cell therapy with tyrosine kinase inhibitors (TKI) aimed to enhance treatment effectiveness.
The study revealed promising outcomes: among 18 patients, the complete molecular remission rate after CD19 CAR-T cell therapy reached 72.2%. Among these patients, subsequent treatment with CD22 CAR-T cells achieved a complete molecular remission rate of 76.9%. At a median follow-up of 13.5 months post CAR-T cell therapy, 16 patients maintained complete hematological remission, while 14 patients sustained complete molecular remission without undergoing allogeneic transplantation. Notably, no CRS (cytokine release syndrome) ≥ Grade 3 or ICANS (immune effector cell-associated neurotoxicity syndrome) occurred during CAR-T cell therapy.
Professor Huang He’s team’s groundbreaking research presented at the ASH conference signifies a leap forward in the treatment of blood-related cancers, signaling a more efficient and accessible era. These findings instill hope for refining treatment strategies and potentially making a significant impact in the field of hematologic oncology.
Beyond the groundbreaking progress in CAR-T cell therapy combined with TKI, the team showcased seven oral presentations and 26 poster exhibitions. These studies encompassed fundamental research on blood disorders, leukemia pathogenesis, acute lymphoblastic leukemia, acute myeloid leukemia, lymphoma, myeloma, hematopoietic stem cell transplantation, and cellular immunotherapy, all crucial for enhancing clinical practices.
We eagerly anticipate further groundbreaking strides by Chinese research teams in cancer treatment studies, anticipating the transformative impact of these research findings in the future.
#ASHAnnualMeeting #HematologyResearch #CARTCellTherapy #StemCellTransplantation #BloodCancer #ClinicalInnovation #OncologyAdvancements #Cancertherapy #MedicalResearch #ASH #CART #CARTTherapy #CARTCell #TKI #tyrosinekinaseinhibitors
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Chinese Research Team New Treatment Shows Promise: CD7 CAR-T Cell Therapy for Relapsed/Refractory AML
Chinese Research Team New Treatment Shows Promise: CD7 CAR-T Cell Therapy for Relapsed/Refractory AML
A recent clinical trial has unveiled a new prospect for treating relapsed/refractory acute myeloid leukemia (AML). The study delved into the safety and efficacy of a natural selection CD7 CAR-T cell (NS7 CAR-T cell) in treating CD7+ relapsed/refractory AML patients.
The research involved 10 cases of CD7+ relapsed/refractory AML, where 30% of AML patients expressed CD7. Following treatment with NS7 CAR-T cell infusion, the results showed that within 4 weeks post-infusion, 70% of patients achieved complete bone marrow remission (CR), with 6 patients achieving a deep remission at the level of minimal residual disease (MRD). Notably, the loss of CD7 was identified as a primary reason for non-response in some patients.
The study also indicated that the majority of patients (80%) experienced mild cytokine release syndrome (CRS) post-infusion, with no observed neurotoxicity.
Furthermore, for select patients, continuing with a second allogeneic hematopoietic stem cell transplantation post NS7 CAR-T cell treatment resulted in promising long-term outcomes. However, further exploration is required for patients who did not undergo consolidative transplants to enhance treatment efficacy.
Professor Lu Peihua(Lu Daopei Hospital) remarked that this study highlights the potential of CD7 CAR-T cells as a bridging therapy before transplantation, demonstrating preliminary therapeutic efficacy for relapsed/refractory AML patients. Nevertheless, a comprehensive evaluation of its efficacy requires a larger sample size and longer-term follow-up.
This preliminary study represents a significant advancement in the field of AML treatment, but collaborative efforts and more research are still necessary. Looking ahead, we anticipate further studies and treatment outcomes to bring more beneficial therapeutic options for the long-term survival of patients, supported by a broader patient cohort and collaborative efforts from the medical community.
The outlook for this CD7 CAR-T cell therapy is promising, especially for AML patients who have undergone various treatments and allogeneic hematopoietic stem cell transplants. We look forward to more in-depth research and treatment outcomes in the future, offering more beneficial treatment choices for long-term survival among patients.
(source: ClinicalTrials.gov registration number NCT04938115
Preliminary results published by Professor Lu Peihua and their team in a top-tier journal)
#AMLResearch #CancerTreatment #CARTTherapy #Leukemia #MedicalBreakthrough #Cancer #AML #Immunotherapy #ClinicalTrials #BloodCancer #PatientCare #HealthcareAdvances #PrecisionMedicine #ScienceAndHealth #MedicalScience #CancerSurvivor #AMLWarriors #ResearchProgress #CancerFree #HopeInTreatment #acutemyeloidleukemia
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
A significant breakthrough in Chinese solid tumor CAR-T therapy, resulting in complete remission for pancreatic cancer patients.
Chinese pharmaceutical company SciCoMed announced a significant breakthrough in treating metastatic pancreatic cancer with its independently developed CAR-T cell therapy targeting Claudin18.2, known as CT041. Pancreatic cancer, often termed the “king of cancers,” presents a significant challenge with low survival rates. However, CT041’s two representative cases have garnered attention: two patients with refractory pancreatic cancer, who failed multiple lines of treatment, received CT041 therapy. The results showcased a substantial reduction in tumor lesions and, in some cases, complete disappearance, offering a glimmer of hope for pancreatic cancer patients.
In the case of a 58-year-old female patient, lung metastases significantly decreased post CT041 treatment. Similarly, a 75-year-old female patient achieved complete remission by the fourth week post-treatment, maintaining remission to date. These successful cases validate the remarkable efficacy of CT041 for refractory pancreatic cancer, sparking interest and anticipation among international experts.
Moreover, CT041 has garnered recognition for its efficacy in the field of digestive system tumors. As the world’s first CAR-T cell therapy targeting Claudin18.2, it demonstrates promising prospects in treating digestive system tumors. Research data illustrates that among 37 patients, 83.3% experienced tumor regression, with an objective response rate of 48.6%. Additionally, CT041 displayed significant effectiveness in late-stage gastric and pancreatic cancer patients, offering hope for future treatments.
The rapid development of CAR-T therapy in China involves over 20 companies contributing significantly. CT041’s success signifies China’s progress toward becoming a global leader in CAR-T therapy. Moving forward, scientists will continue efforts to enhance efficacy and reduce side effects, providing a ray of hope for more late-stage cancer patients.